An increased Th1/CTL response is associated with chemosensitivity and increased survival in HER2 and basal breast cancer patients (Finak et al., 2008; DeNardo et al., 2009; Ursini-Siegel et al., 2010; West et al., 2011). Here, ERBB2 is linked to breast carcinoma.